Release Date: August 3, 2023
Expiration Date: August 3, 2024
Note: If you have already attended the 2023 Summit Series Live Event, you will not be able to log enduring credits
Activity Overview
This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will review traditional and novel agents in the management of ocular hypertension (OH) and open-angle glaucoma (OAG), including monotherapy and combination regimens. Attention will be given to mechanisms of action, factors that need to be considered in treatment decision-making, and strategies for improving treatment adherence.
Target Audience
This activity is designed for an audience of ophthalmologists, optometrists, and other members of the healthcare team who treat patients with glaucoma.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Describe the safety and efficacy of FDA-approved and emerging topical treatments for OH and OAG
- Explain the best approaches for topical treatment selection and ongoing management of OH and OAG
- Discuss strategies for improving patient adherence to topical treatments for OH and OAG
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at
ketrea@akhcme.com
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and International Healthcare Media, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.00
AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE - Optometrists
AKH Inc., Advancing Knowledge in Healthcare designates this asynchronous activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported by independent educational grants from Alcon, Genentech, Regenxbio, Tarsus, Théa, and Visus.
|
Name
|
Relationship
|
Commercial Interest
|
|
Session Faculty
|
|
|
| Pinakin Davey, OD, PhD, FARVO (moderator)
|
Consultant, Stock, Speaker
|
EyePromise LLC St Louis Missouri
|
|
Consultant |
Guardion Health Sciences |
|
Stock |
Globe Biomedical |
|
Speaker |
Sanofi Genzyme |
|
Speaker |
Innova USA |
|
|
|
| Shan Lin, MD (faculty)
|
Consultant
|
IRIDEX Corporation
|
|
|
Stock
|
Claris
|
|
|
Speaker
|
Bausch + Lomb |
|
Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education & Operations
|
N/A
|
Nothing to disclose
|
|
Michele Bielarski, RN (planner/reviewer)
|
N/A
|
Nothing to disclose
|
|
AKH Inc. Staff and Planners
|
N/A
|
Nothing to disclose
|
|
International Healthcare Media, LLC Staff and Planners
|
N/A
|
Nothing to disclose
|
|
All of the relevant financial relationships listed for these individuals have been mitigated.
|
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.
